Optical induction of autophagy via Transcription factor EB (TFEB) reduces pathological tau in neurons.


FULLTEXT
Published:
06.23.2020
|
Last Revised:
06.22.2020
PMID:
32208437
PloS one
Journal Article,Research Support, N.I.H., Extramural,Research Support, Non-U.S. Gov't

Department of Molecular Genetics and Microbiology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States of America.
Department of Neurosciences, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States of America.
Department of Molecular Genetics and Microbiology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States of America.,Autophagy Inflammation and Metabolism Center of Biomedical Research Excellence (CoBRE), University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States of America.
Department of Neurosciences, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States of America.
Department of Molecular Genetics and Microbiology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States of America.

Abstract

Pathological accumulation of microtubule associated protein tau in neurons is a major neuropathological hallmark of Alzheimer's disease (AD) and related tauopathies. Several attempts have been made to promote clearance of pathological tau (p-Tau) from neurons. Transcription factor EB (TFEB) has shown to clear p-Tau from neurons via autophagy. However, sustained TFEB activation and autophagy can create burden on cellular bioenergetics and can be deleterious. Here, we modified previously described two-plasmid systems of Light Activated Protein (LAP) from bacterial transcription factor-EL222 and Light Responsive Element (LRE) to encode TFEB. Upon blue-light (465 nm) illumination, the conformation changes in LAP induced LRE-driven expression of TFEB, its nuclear entry, TFEB-mediated expression of autophagy-lysosomal genes and clearance of p-Tau from neuronal cells and AD patient-derived human iPSC-neurons. Turning the blue-light off reversed the expression of TFEB-target genes and attenuated p-Tau clearance. Together, these results suggest that optically regulated TFEB expression unlocks the potential of opto-therapeutics to treat AD and other dementias.

GrantID: R21 NS093442, Acronym: NS, Agency: NINDS NIH HHS, Country: United States | GrantID: R01 NS083704, Acronym: NS, Agency: NINDS NIH HHS, Country: United States | GrantID: R21 NS077089, Acronym: NS, Agency: NINDS NIH HHS, Country: United States | GrantID: P20 GM121176, Acronym: GM, Agency: NIGMS NIH HHS, Country: United States